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Abstract The aim of this study was to determine the
threshold of fracture probability at which interventions
became cost-effective in men and women, based on data
from Sweden. We modeled the effects of a treatment
costing $500 per year given for 5 years that decreased
the risk of all osteoporotic fractures by 35% followed by
a waning of effect for a further 5 years. Sensitivity
analyses included a range of effectiveness (10-50%) and
a range of intervention costs ($200–500/year). Data on
costs and risks were from Sweden. Costs included direct
costs, but excluded indirect costs due to morbidity.
A threshold for cost-effectiveness of approximately
$45,000/QALY gained was used. Cost of added years
was included in a sensitivity analysis. With the base case
($500 per year; 35% efficacy) treatment in women was
cost-effective with a 10-year hip fracture probability that
ranged from 1.2% at the age of 50 years to 7.4% at the
age of 80 years. Similar results were observed in men
except that the threshold for cost-effectiveness was
higher at younger ages than in women (2.0 vs 1.2%,
respectively, at the age of 50 years). Intervention
thresholds were sensitive to the assumed effectiveness
and intervention cost. The exclusion of osteoporotic
fractures other than hip fracture significantly increased
the cost-effectiveness ratio because of the substantial
morbidity from such other fractures, particularly at
younger ages. We conclude that the inclusion of all
osteoporotic fractures has a marked effect on interven-
tion thresholds, that these vary with age, and that
available treatments can be targeted cost-effectively to
individuals at moderately increased fracture risk.
Keywords Cost-effectiveness Æ Cost of added years Æ
Hip fracture Æ Intervention threshold Æ Osteoporotic
fracture
Introduction
There is a growing opinion that intervention thresholds
for osteoporosis should be based on absolute risk
(probability) of fracture rather than solely on diagnostic
thresholds provided by the T-score of bone mineral
density (BMD) [1, 2]. A similar approach is used in
cardiovascular disease where absolute risk has been used
to determine intervention thresholds for primary pre-
vention with lipid lowering agents [3, 4, 5, 6, 7].
The setting of intervention thresholds in osteoporosis
should take account of the multiple outcomes of osteo-
porosis—namely the different fracture outcomes and
their associated morbidity. We have previously charac-
terized the morbidity that arises from osteoporotic
fractures so that the fracture risk can be weighted
according to the morbidity occasioned by each osteo-
porotic fracture [8]. The technique reduces fracture risk
to a common currency rather than considering the
multiple outcomes that complicate risk assessment. In
addition, the weightings are based on utilities lost (dis-
utility), so that they can be used for health economic
assessment. This and other approaches have been used
to characterize intervention thresholds of fracture risk in
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women that can be justified from a cost-effectiveness
perspective [9, 10].
Since then, recent studies in patients have suggested
that the morbidity arising from vertebral fractures is
very significant, and far greater than hitherto appreci-
ated based on expert opinion [11, 12, 13, 14, 15, 16].
Indeed, the loss of quality of life in the 1st year after
fracture may be of the same order of magnitude as that
for hip fracture [13, 17]. In addition, there is now more
epidemiological information available in men. Such data
suggest that fracture risk for any given BMD (at the hip
or spine) is similar in men and women [18, 19, 20, 21],
and that additional risk factors such as prior fracture,
corticosteroid use, and low body mass index have a
similar significance in men as they have in women [21,
22, 23]. The objectives of this paper were to update
thresholds of risk at which intervention could be con-
sidered cost-effective in women and additionally to
provide intervention thresholds for men, modeled on the
population of Sweden. For this purpose we chose a
health service perspective, based on direct costs, but a
societal perspective was examined in a sensitivity anal-
ysis.
Methods
The model used was based on a Markov model using
data on fracture risk derived from the population of
Sweden [24, 25]. Direct costs were defined as interven-
tion costs, including those from diagnosis, drugs, and
monitoring of treatment minus the savings from a
reduction in the future number of osteoporotic fractures
needed to be treated. Indirect costs were not included
in this analysis. Costs, using values for the years 2000–
2001, were derived in SEK but were converted to US$
at a conversion rate for the year 2001 ($1=9.53 SEK).
Fracture costs were estimated as the difference between
the cost during the years after fracture and the costs in
the year preceding the fracture. The costs of hip fracture
in the 1st year rose from $8,636 for those patients be-
tween the ages of 50 and 64 years, to $23,200 at the age
of 85 years or more [26]. Additional costs in the 2nd and
subsequent years were assumed to be constant ($4,785).
Since costings for all types of osteoporotic fractures and
age weights were not available, the costs of other oste-
oporotic fractures were assumed to be proportional to
the disutility incurred by these fractures compared with
that of hip fracture [8]. A recent cost analysis in
Rochester indicated that the total incremental costs of
all fractures other than those at the hip were 47 and 46%
higher than the costs of hip fractures in men and women,
respectively. The morbidity of nonhip osteoporotic
fractures was 39 and 47% higher than for hip fracture
in men and women, respectively, suggesting the appro-
priateness of this assumption [27, 28].
In a sensitivity analysis we examined the effects of
intervention on clinical vertebral fracture without effects
on hip fracture. The cost of a clinical vertebral fracture
was taken as $3,200, based on empirical data from
Malmo [13] and similar to incremental costs calculated
for the United States [29].
The avoidance of fracture was assumed to reduce
associated deaths only in the 1st year after fracture.
Thus, a minority of fracture-associated mortality was
assumed to be prevented in accordance with empirical
and epidemiological data [30, 31]. Costs from increased
survival were excluded in the base-case analysis in order
to facilitate comparisons with other published estimates
of cost-effectiveness in osteoporosis. These costs were
included in a sensitivity analysis. A threshold value of
$45,000 per QALY gained compared to no treatment
was taken as an indication of cost-effectiveness using
direct costs in line with the recommendations of the
National Institute for Clinical Excellence, United
Kingdom (NICE) [32]. This is somewhat higher than
that proposed by the NOF in 1998 [9] and previously
used by ourselves [10, 25]. A threshold of $64,000/
QALY gained was used in sensitivity analyses where cost
of added years was included [7]. The higher bench-mark
value is commonly used when costs in added years of life
are included [7, 33].
An intervention of 5 years was assumed, targeted to
the male or female population at a given 10-year hip
fracture probability at any given age. The hip fracture
probability varied from 0.5 to 8%. The 5-year treatment
was chosen to approximate the time period for which
there are direct or indirect clinical data on intervention
effects. After stopping intervention, the risk reduction
was assumed to reverse in a linear manner over a 5-year
period [25, 34]. We used a relative risk reduction (RRR)
of 35% for all osteoporotic fractures from the onset of
treatment as the base case, which approximates the effect
of hormone replacement treatment on all fractures [35]
and vitamin D with calcium on hip fracture risk [36]. We
additionally examined an effectiveness of 20% and 50%.
The latter approximates the average risk reduction from
clinical trials with the bisphosphonates [37, 38, 39, 40,
41] and from observational evidence with the recent use
of estrogens [42, 43, 44]. The former accommodates an
imperfect compliance, at least with regard to efficacy.
Finally, we modeled an efficacy of 10%, since even
treatments with low efficacy but low costs may still be
targeted cost-effectively [45].
Four different intervention cost levels of $200, $300,
$400, and $500 per annum were investigated. The
highest cost was used for the base case. The two higher
costs approximate the cost in Sweden of transdermal
hormone replacement treatment and bisphosphonate
intervention, respectively, together with the costs of
monitoring for a yearly hospital visit and a BMD test
every 2 years. The lower costs encompass cheaper forms
of hormone replacement therapy and calcium with and
without vitamin D, and vitamin D alone. For the cal-
culation of intervention thresholds, the base-case
treatment (35% efficacy/$500 p.a.) was directed at the
male and female population over a range of fracture
probabilities and age, and the probability of hip fracture
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computed at which costs crossed the threshold for cost-
effectiveness. All simulations were undertaken using a
discount rate of 3% for both costs and benefits (QALY).
For hip fracture rates we used national data from
Stockholm 1990 [46]. For vertebral fractures (those
coming to clinical attention), proximal humerus, and
Colles fracture, we used data from Malmo [47]. For
other osteoporotic fractures (distal femur, proximal ti-
bia, ribs, sternum, scapula, pelvis, shaft of humerus, and
clavicle), we used rates calculated for Sweden (1991–
1997) [47]. Tibial fractures in men were not considered to
be due to osteoporosis [8]. Age-specific fracture rates
and mortality were assumed not to change over the
lifetime of individuals. The assumption on mortality
underestimates lifetime risk [48], but has little impact
over the intervention period.
Utility loss following a fracture was assumed to be
similar in men and women. For hip fracture a multi-
plier of 0.79 was applied to health state values for age
to compute loss of QALYs in the 1st year and 0.9 in
subsequent years [25]. The utility loss for all other
fractures was derived from estimates of the National
Osteoporosis Foundation [9] with minor modifications
[17]. For the purposes of modeling, excess morbidity
from all other fractures was computed as a ratio of that
due to hip fracture at any given age [8]. Excess mor-
bidity was 6.1 in women between the ages of 50 and
55 years—i.e., the morbidity (and costs) associated with
other osteoporotic fractures was 6.1 times than that
accounted for by hip fractures alone. For men this was
4.5 at the same ages. Excess morbidity decreased with
age to approximately 1.5 from the ages of 80 years
onwards [17].
When a person had a fracture, subsequent costs for
intervention as well as further fractures were assumed to
be zero. We estimated, therefore, the cost-effectiveness
of preventing only the first fracture since, if it were cost-
effective to prevent the first fracture, it would probably
also be cost-effective to prevent the second, due to the
higher risk in the population with a previous fracture
[49]. When an individual had a fracture, all future costs
related to that fracture were included in the cost per
fracture for the 1st year [50]. Excess mortality after
fracture was included for the 1st year after fracture [25]
and assumed to be the same as the general population
for the 2nd and subsequent years.
Results
The cost-effectiveness of the base-case treatment ($500)
and of midrange efficacy (35% effectiveness) is shown in
Fig. 1 at different ages and different hip fracture prob-
abilities. As expected, cost-effectiveness improved at any
age with increasing fracture probability, due to the
higher risk of fracture and thus the greater number of
fractures avoided. For any given hip fracture probabil-
ity, cost-effectiveness improved with decreasing age since
more nonhip fractures were avoided at the younger ages.
Similar findings were noted in men with the exception
that it was less cost-effective to treat men at the age of
50 years for any given fracture probability, mainly due
to the exclusion of tibial fractures as being osteoporotic
in men. At the age of 60 years and more there was little
difference in cost-effectiveness ratio between men and
women at any given 10-year probability.
The threshold probability of hip fracture (10-year
risk) at which intervention (35% RRR) became cost-
effective is shown in Table 1 and Fig. 2 for the base case.
In women, this ranged from 1.17 to 7.40% depending on
age. The lower threshold probability at younger ages
reflects the influence of fractures other than the hip and
the longer survival of younger women. In men the
threshold probabilities were higher than in women up to
the age of 60 years due to the exclusion of tibial frac-
tures (which were not considered to be due to osteopo-
rosis). Above the age of 65 years the threshold
probabilities below which it was cost-effective to inter-
Fig. 1 Cost-effectiveness of an
intervention costing $500
per annum with an efficacy of
35%, according to age and
hip fracture probability. The
threshold for cost-effectiveness
is set at $45,000 per
QALY gained (horizontal line).
Note the logarithmic scale
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vene were somewhat lower in men than in women, due
to the higher mortality in men.
In women it was cost-effective to treat at average risk
for age from the age of 65 years whereas in men it was
cost-effective to treat from the age of 85 years (see
Table 1).
The impact of averting hip fracture alone, hip plus
spine plus forearm fracture, or all osteoporotic fractures
is shown in Table 2 for a male aged 65 years. When
therapy was assumed to decrease hip fracture only, it
was not cost-effective to intervene unless the 10-year hip
fracture probability exceeded about 10%. Where treat-
ment had effects on hip, spine, and forearm fractures,
the threshold probability was approximately 7%. Where
all osteoporotic fractures were assumed to decrease with
intervention (i.e., the base case), it was cost-effective to
intervene with a hip fracture probability of 3.4%.
Effects on hip fracture had a greater quantitative
impact than effects on spine fracture. For example, in
men aged 75 years with a twofold increase in risk of hip
fracture, the cost-effectiveness ratio was $59,000 where
no effects on vertebral fracture were assumed (Fig. 3). In
contrast, in men of the same age and a twofold increase
in vertebral fracture risk, the cost-effectiveness ratio was
$87,000 where no effect on hip fracture was assumed.
Where effects on both fracture types were assumed, cost-
effectiveness improved ($47,500).
The impact of including costs of added years of life is
shown in Table 3. Their inclusion increased the cost-
effectiveness ratio, an effect that increased with
advancing age. At the age of 50 years their inclusion
decreased the threshold probability at which treatment
became cost-effective. By contrast above the age of
75 years, the threshold probability was higher than
when the costs of added years was excluded (Table 3).
Further one-way sensitivity analyses were undertaken
for women aged 60 years to compare with a base-case
hip fracture probability at the threshold of cost-effec-
tiveness. Using no discount rate for benefits, the hip
fracture probability threshold improved by 15%
(Table 4) since costs were largely confined to the treat-
ment period, whereas benefits continued to accrue after
the intervention stopped. For the same reason, the
probability threshold improved by 29% when the offset
time was assumed to be 10 rather than 5 years. Con-
versely, reducing the offset time, adversely affected the
Table 1 Threshold 10-year hip fracture probability at which
intervention became cost-effective
Age
(years)
Hip fracture proba-
bility (% at 10 years)
Hip fracture proba-
bility (%at 10 years)a
Men Women Men Women
50 1.98 1.17 0.41 0.55
55 2.36 1.80 0.68 1.16
60 2.96 2.73 1.17 2.35
65 3.72 3.98 2.02 4.54
70 4.74 5.11 3.22 7.67
75 5.42 6.08 4.46 12.24
80 6.46 7.40 6.23 18.38
85 6.31 7.23 7.25 21.90
90 6.16 6.62 8.03 22.00
aAverage probability in the general population for age and sex
Fig. 2 Intervention thresholds
in men and women expressed as
10-year hip fracture probability
according to age (solid lines)
and average 10-year hip
fracture probability (bars).
Note the logarithmic scale
Table 2 Cost-effectiveness of intervention in men aged 65 years
according to the type of fracture averted
RR 10-year
hip fracture
probability
(%)
Cost/QALY gained ($000)
Hip Hip, spine,
and forearm
All osteoporotic
fractures
1 1.7 378 221 105
2 3.4 231 104 39
3 5.0 113 65 21
4 6.6 80 46 10
5 8.1 60 34 3.7
6 9.7 47 27 )0.5
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probability threshold. Alterations in the duration of
treatment had modest effects on cost-effectiveness. Sen-
sitive variables affecting threshold probabilities were the
assumed efficacy and cost of intervention.
Discussion
In this paper we used a simulation model to investigate
the cost-effectiveness of a 5-year treatment to prevent
osteoporotic fractures in men and women. Major
determinants of cost-effectiveness included the age of the
individual, the cost of intervention, and the fracture
probability. Our analysis shows that it is possible to offer
cost-effective intervention even for men and women at
moderate risk. For example, for agents of intermediate
effectiveness (35%) it was cost-effective to treat men
aged 85 years and women aged 65 years at average risk
with the most expensive intervention, assuming that
intervention could be shown to be effective in such a
population. Previous estimates examining the cost-
effectiveness of interventions on the basis of hip fracture
alone suggest that intervention in women of average risk
at the age of 80 years is cost-effective [51] consistent with
the present analysis. Intervention thresholds determined
on hip fracture probability alone would neglect the
many other fractures, particularly in younger age groups
where the frequency of fractures at other sites is much
higher than in the elderly [8, 52]. Even in the elderly, hip
fractures represent fewer than 50% of fractures in men
and women aged 80 years or more [8, 52, 53]. Thus, the
inclusion of additional fractures due to osteoporosis
decreases the threshold substantially as also shown in
our sensitivity analysis (see Table 2).
In an earlier paper we published intervention
thresholds for women [10], but this has now been up-
dated largely because of the awareness that the mor-
bidity of vertebral fracture is substantially higher than
previously assumed [17]. The impact of this revision is to
decrease the threshold of risk at which intervention be-
comes cost-effective, particularly in younger individuals
in whom vertebral fractures are more common than hip
Fig. 3 Cost-effectiveness
($000/QALY gained) of
treatment in men aged 75 years
according to relative risk (RR).
Treatment is variously assumed
to have an effect only on hip
fracture risk, vertebral fracture
risk, or both
Table 3 Relative risk of hip fracture and 10-year hip fracture
probability at which intervention became cost-effective when
including costs of added years of life
Age (years) Men Women
RR 10-year
probability (%)
RR 10-year
probability (%)
50 4.00 1.57 1.73 0.94
55 2.90 1.91 1.28 1.47
60 2.25 2.56 0.98 2.31
65 1.75 3.44 0.76 3.50
70 1.47 4.59 0.60 4.78
75 1.27 5.58 0.47 6.11
80 1.16 7.15 0.39 7.94
85 1.04 7.52 0.32 6.90
90 0.92 7.44 0.28 7.67
Table 4 Sensitivity analysis of 10-year hip fracture probability
around a base-case assumption of a 60-year-old women with a hip
fracture probability at the threshold for cost-effectiveness
10-year
probability (%)
Variance (%)
Discounted benefits 0% 2.29 )15
3%a 2.73 0
6% 3.13 +15
Offset time 0 years 4.05 +48
5 yearsa 2.73 0
10 years 1.95 )29
RR of fracture 1.00 2.35 )14
1.17a 2.73 0
1.50 3.46 +47
Duration of treatment 3 years 2.38 )13
5 yearsa 2.73 0
10 years 2.87 +5
15 years 2.74 0
Efficacy of treatment 10 RRR% 14.0 +412
20 RRR% 5.49 +101
35 RRR%a 2.73 0
50 RRR% 1.85 )32
Cost of treatment $200 0.99 )64
$300 1.53 )44
$400 2.11 )23
$500a 2.73 0
aBase case
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fracture, but the effect is relatively small. From our
previous estimates, intervention thresholds, expressed as
10-year hip fracture probabilities, were 1.37, 2.14, 3.18,
and 4.14% at the ages of 50, 55, 60, and 65, respectively.
The current estimates (see Table 1) are approximately
15% lower in women.
The impact of adopting these thresholds depends
upon the accuracy with which individuals whose level of
risk is at or higher than the threshold can be identified.
For BMD measured at the hip, risk increases approxi-
mately 2.6-fold for each SD decrease in BMD [54].
Gradients of risk can be improved by the consideration
of other independent risk factors [2]. The effect of these
considerations on screening strategies is shown in
Table 5. At the age of 50 years, approximately 10% of
Swedish women would be identified to be at high risk, a
proportion that increases with age, but decreases with
higher gradients of risk. In countries with a lower hip
fracture probability, the proportion detected would be
markedly lower.
To our knowledge the present study is the first to
characterize intervention thresholds in men. As ex-
pected, these are broadly similar to those found in wo-
men, at least from the age of 60 years or more (see
Table 1). For men aged 50 or 55 years, intervention
thresholds are higher in men than in women. This is
explained by the exclusion of tibial fractures since there
is little evidence that these can be considered to be
osteoporotic in men [8].
The threshold of cost-effectiveness we used was
$45,000 (£30,000) per QALY gained, consistent with
the threshold that has been recommended by NICE in
the United Kingdom [32]. The use of a lower threshold
as undertaken previously by ourselves and others [9,
51, 55] would not markedly alter our overall conclu-
sions (see Fig. 1). In a sensitivity analysis we included
cost of added years since their inclusion is recom-
mended when taking a societal perspective [55, 56, 57].
The effect of adding these costs is to decrease the
fracture probability at which treatment becomes
cost-effective at the age of 50 years (see Table 3). In the
elderly the reverse pertains—namely, that the threshold
probability is lower when costs of added years are ex-
cluded. Thus, the effect of not adding future costs
biases cost-effectiveness in favor of interventions di-
rected at the elderly, and conversely discriminates
against the young. For this reason their exclusion dis-
enfranchises the younger population in whom many
osteoporotic fractures occur.
The wide range of intervention costs and efficacy
poses problems in setting intervention thresholds since
changes in the assumptions for both have marked effects
on cost-effectiveness. The most conservative scenario is
the most expensive intervention and the lowest efficacy.
Conversely, the most exuberant would be to choose the
level of risk at which the cheapest intervention had the
greatest effectiveness. From a societal perspective a
basket of treatments are used with a range of efficacy
and costs. For the base case, we assumed (as previously
published [10]) an average effectiveness of 35% on all
osteoporotic fractures but the highest cost of interven-
tion ($500).
An important finding from the present study is that
the threshold of hip fracture probability at which
treatment becomes cost-effective is lower with decreasing
age (see Table 1). Indeed, for intervention at the age of
50 years a 10-year probability that exceeds 1.2% is cost-
effective in women. By contrast, for those aged 80 years,
treatment became cost-effective with a hip fracture
probability of 7.4%. This appears to be paradoxical, but
arises because it is assumed that intervention decreases
the risk of all osteoporotic fractures. In younger women,
proportionately more fractures occur at sites other than
the hip. Thus, for a given hip fracture probability, more
fractures at sites other than the hip are averted. At the
age of 50 years, women have a hip fracture probability
of 1.2% which is twice the average hip fracture proba-
bility of the general population, but at the age of
80 years, a probability of 7.4% is lower than the average
hip fracture probability for that age (see Table 1). In a
practical sense one would offer cost-effective treatment
to a 50-year-old woman only where her risk of hip
fracture were double that of the general population, but
offer the same intervention for the same cost-effective-
ness to an 80-year-old woman at average risk. Thus, the
effect of age to increase the hip fracture probability at
which treatments become cost-effective should not be
misconstrued to infer that the younger the age, the more
cost-effective treatments become. Indeed, the converse is
true.
For women aged 70 years or more, it is, using the
base case, cost-effective to treat women at the average
population risk (see Fig. 2). For example, it is cost-
effective to treat women at the age of 70 years with a
10-year hip fracture probability of 5.1%, whereas the
population probability at this age is 7.7% (see Table 1).
It is, however, not entirely certain whether the inter-
vention threshold in the elderly should be below the
average hip fracture probability for age and sex.
Table 5 The percentage of men and women at the ages shown
who would be identified to have a risk that exceeds the intervention
threshold according to the gradient of fracture risk / SD, of the
assessment algorithm specified
Age (years) Proportion of population identified (%)
Gradient of
risk = 2.6/SD
Gradient of
risk = 4.0/SD
Men Women Men Women
50 1.4 9.7 3.1 10.4
55 3.4 16.9 5.2 15.3
60 6.8 26.0 8.2 21.0
65 12.5 37.0 12.4 27.7
70 18.0 49.6 16.0 35.5
75 24.4 62.9 20.0 44.6
80 30.2 72.6 23.5 52.0
85 37.5 80.7 28.0 59.2
90 43.0 84.3 31.4 62.9
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The reason is that most trials of intervention have
targeted men and women with low bone mineral density,
with a T-score for BMD commonly <)2.0 or
<)2.5 SD, so that there is less experience of treating
individuals with higher values for BMD. Recent studies
suggest that efficacy of interventions on vertebral frac-
ture risk is not markedly affected by baseline BMD [58,
59, 60]. For nonvertebral fractures the information base
is less but would suggest that antifracture efficacy with
bisphosphonates is less marked in individuals with the
higher values for BMD [61, 62]. On the other hand,
hormone replacement treatment has also been shown to
decrease fracture risk when targeted to the general
population [35]. Until these uncertainties are resolved it
would seem unwise to recommend intervention in indi-
viduals whose risk is not increased above that of the
population of the same age and sex.
Our conclusions are based on a number of assump-
tions. A key assumption used in the model concerns the
efficacy of treatment. We assumed that if hip fracture
risk decreases by a given proportion as a result of
treatment, then a comparable effect would be seen for
other osteoporotic fractures. This assumption may not
be warranted, and for this reason we chose intermediate
levels of efficacy. A further important assumption con-
cerning the effectiveness of an intervention is the dura-
tion that an effect persists after stopping treatment [25].
There is a great deal of uncertainty over the offset time
of many treatments. Relatively rapid offset times of a
few years have been observed with calcium, calcitonins,
and vitamin D metabolites. Longer offset times are
described with the bisphosphonates, estrogens, and
tamoxifen, and more recently with parathyroid hormone
[25, 63]. Our assumption of a 5-year offset time is
therefore conservative, and longer offset times have been
shown to improve markedly cost-effectiveness [25] as
shown in the present study. A further consideration is
that we modeled a fixed treatment time of 5 years, but
altering the duration of intervention has modest effects
on costs and effectiveness [34] (see Table 4).
A further uncertainty arises from our use of utility-
weighted fracture risks. This approach weights the
incidence of different osteoporotic fractures by their
disutility. Thus, a single hip fracture in women aged
50 years is equivalent to approximately two vertebral or
four humeral fractures in terms of the morbidity caused
[17]. This approach avoids the numerous transition
states required in a Markov model for the multiple
outcomes. The approach also assumes, however, that
direct costs of different fractures are proportional to
their disutility. The assumption appears to be reason-
able, at least as judged by hospital costs (see ‘‘Meth-
ods’’). A further assumption is that deaths arising from
fractures are proportional to their disutility. The
assumption has not been tested, though it is of relevance
that high mortality risks are reported for clinically overt
vertebral fractures [64, 65, 66, 67] and other long bone
fractures [65] with the exception of those at the distal
forearm [64, 65, 66]. The proportion of deaths that are
causally related to hip fractures is unknown but is esti-
mated to be approximately 25%—similar to estimates
for vertebral fracture [68, 69]. Since not all deaths are
likely to be causally related we modeled only those
deaths occurring in the 1st year as being potentially
reversible with treatment.
It is also important to recognize that our model was
populated with information available from Sweden.
There is a great deal of heterogeneity in fracture prob-
ability around the world [70, 71, 72, 73] as well as in the
costs of fracture and costs of intervention. For countries
with low hip fracture rates, as found in developing
countries, the relative risk at which intervention is cost-
effective will be higher, though the absolute risk at which
intervention is cost-effective would not change assuming
comparable costs. Thus, in countries with fracture rates
lower than Sweden, a lower proportion of the popula-
tion would be identified for treatment. Intervention
thresholds would, however, change with differences in
costs, particularly fracture costs, which in most coun-
tries are poorly documented. Notwithstanding, the
selection of an intervention threshold to cover the most
expensive Swedish treatment with intermediate efficacy
may provide some buffer for these variations in costs.
A further important variable in other health care
settings is willingness to pay for treatment. The gross
domestic product (GDP) varies markedly in different
regions of the world. In Sweden the GDP/capita is
estimated at $25,400 in 2002, but is only $7,000 in
Turkey. Thus, for the same fracture risk and the same
costs, treatment will be less affordable (at least to health
services) in Turkey than in Sweden. On the other hand,
individuals in Turkey, rather than society as a whole,
may be willing to pay ‘‘Swedish prices’’ for health care.
For all these reasons it will be important to define
intervention thresholds on a country-by-country basis
that takes into account the setting for service provision
and willingness to pay, as well as considerations of
absolute costs.
In this paper we have modeled only the effects of
osteoporotic fractures. The impact of interventions that
have generalized extraskeletal benefits and risks would
markedly alter cost-effective intervention thresholds [46].
The obvious examples are hormone replacement treat-
ment and the selective estrogen receptor modulators.
Both appear to affect breast cancer, though in different
directions [74, 75], and both decrease markers of car-
diovascular morbidity [74, 75, 76], though no favorable
effects of hormone replacement on cardiovascular events
have been shown [35].
Within these limitations a 10-year probability of hip
fracture that varies according to age provides a useable
intervention threshold that can be considered in the
development of assessment and treatment guidelines in
osteoporosis.
Acknowledgements We are grateful to the International Osteopo-
rosis Foundation, Pfizer, Alliance for Better Bone Health, IGEA,
Lilly Research Centre, Hologic, Novartis, Wyeth, and Roche for
their unrestricted support of these studies.
12
References
1. Kanis JA, Gluer C-C, for the Committee of Scientific Advisors,
International Osteoporosis Foundation (2000) An update on
the diagnosis and assessment of osteoporosis with densitome-
try. Osteoporos Int 11:192–202
2. Kanis JA (2002) Diagnosis of osteoporosis and assessment of
fracture risk. Lancet 359:1929–1936
3. Anonymous (2001) Statin therapy: what now? Drug Ther Bull
39:17–21
4. Ramsay LE, Haq IU, Jackson PR, Yeo WW (1996) The
Sheffield table for primary prevention of coronary heart dis-
ease: corrected. Lancet 348:1251–1252
5. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM,
Payne JN (1996) Targeting lipid-lowering drug therapy for
primary prevention of coronary artery disease: an updated
Sheffield table. Lancet 348:387–388
6. Wood D, DeBacker G, Faergemon O, Graham I, Mancia G,
Pyoralle K (1998) Prevention of coronary heart disease in
clinical practice: recommendations of the second joint task
force of European and other societies on coronary prevention.
Artherosclerosis 140:199–270
7. Johannesson M (2001) At what coronary risk level is it cost-
effective to initiate cholesterol lowering drug treatment in pri-
mary prevention. Eur Heart J 22:919–925
8. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson
A (2001) The burden of osteoporotic fractures: a method for
setting intervention thresholds. Osteoporos Int 12:417–427
9. National Osteoporosis Foundation (1998) Osteoporosis: review
of the evidence for prevention, diagnosis and treatment and
cost-effectiveness analysis. Osteoporos Int 8[Suppl 4]:1–88
10. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B
(2002) Intervention thresholds for osteoporosis. Bone 31; 26–31
11. Merlino LA, Bagchi I, Taylor TN, Utrie P, Chrischilles E,
Sumner W, Mudano A, Saag KG (2001) Preferences for frac-
tures and other glucocorticoid-associated adverse events among
rheumatoid arthritis patients. Med Decis Making 21:122–132
12. Gabriel SE, Kneeland T, Melton LJ et al (1999) Health related
quality of life in economic evaluations for osteoporosis: whose
values should we use? Med Decis Making 19:141–148
13. Zethraeus N, Borgstrom F, Johnell O, Kanis JA, Jonsson B
(2002) Costs and quality of life associated with osteoporosis
related fractures: results of a Swedish survey. Working Paper
Series in Economics and Finance, Report 512. Stockholm
School of Health Economics, Stockholm
14. Tosteson ANA, Gabriel SE, Grove MR, Moncur MM, Knee-
land TS, Melton LJ (2001) Impact of hip and vertebral frac-
tures on quality adjusted life years. Osteoporos Int 12:1042–
1049
15. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud
K, Segal M, Genant HK, Cummings SR (1998) The association
of radiographically detected vertebral fractures with back pain
and function: a prospective study. Ann Intern Med 128:793–
800
16. Nevitt, MC, Thompson, DE, Black, DM, Rubin, SR, Ensrud,
K, Yates, AJ, Cummings, SR for the fracture intervention trial
research group (2000) Effect of alendronate on limited-activity
days and bed-disability days caused by back pain in postmen-
opausal women with existing vertebral fractures. Arch Intern
Med 160:77–85
17. Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, De
Laet C, Jonsson B (2003) The risk and burden of vertebral
fracture in Sweden. Osteoporos Int (in press)
18. O’Neill TW, Lunt M, Silman AJ, Felsenberg D, Benevolens-
kaya LI, Bhalla A, Cannata JB, Cooper C, Crabtree N, De-
queker J, Hoszowski J, Jajic K, Kanis JA, Kragl G, Lopez Vaz
A, Lorenc R, Lyritis G, Masaryk P, Miazgowski T, Parisi G,
Pols HAP, Poor G, Reid DM, Scheidt-Nave C, Stepan G,
Todd C, Weber K, Woolf AP, Reeve J (2002) The relationship
between bone density and incident vertebral fracture in men
and women. J Bone Miner Res 17:2214–2221
19. De Laet CEDH, van Hout BA, Burger H, Weal AEAM,
Hofman A, Pols HAP (1998) Hip fracture prediction in elderly
men and women: validation in the Rotterdam Study. J Bone
Miner Res 13:1587–1593
20. De Laet CEDH, van der Klift M, Hofman A, Pols HA (2002)
Osteoporosis in men and women: a story about bone mineral
density thresholds and hip fracture risk. J Bone Miner Res
17:2231–2236
21. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D (2001)
Diagnosis of osteoporosis and fracture threshold in men. Calcif
Tissue Int 69:218–221
22. Johnell O, De Laet C, Johansson H, Melton LJ, Eisman J,
Reeve J, Tenenhouse A, McCloskey EV, Kanis JA (2002) Oral
corticosteroids increase fracture risk independently of BMD.
Osteoporos Int 13[Suppl 1]:S14
23. De Laet C, Johansson H, Johnell O, Kanis JA, McCloskey EV,
Mellstrom D, Melton LJ, Oden A, Delmas P, Geusens P,
Oglesby A, Eisman J, Pols H, Reeve J, Silman A, Tenenhouse
A (2003) A meta-analysis of body mass index (BMI) as a pre-
dictor of fracture risk. J Bone Miner Res (in press)
24. Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995)
Cost-effectiveness of fracture prevention in established osteo-
porosis. Osteoporos Int 5:136–142
25. Jonsson B, Kanis JA, Dawson A, Oden A, Johnell O (1999)
Effect and offset of effect of treatments for hip fracture on
health outcomes. Osteoporos Int 10:193–199
26. Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G
(1997) The cost of a hip fracture. Acta Orthop Scand 68:13–17
27. Gabriel SE, Tosteson ANA, Leibson CL, Crowson CS, Pond
GR, Hammond CS, Melton LJ (2002) Direct medical costs
attributable to osteoporotic fractures. Osteoporos Int 13:323–
330
28. Melton LJ, Gabriel SE, Crowson CS, Tosteson ANA, Johnell
O, Kanis JA (2003) Cost equivalence of different osteoporotic
fractures. Osteoporos Int 14:383–388
29. Burge R, Puelo E, Gehlbach S, Worley D, Klar J (2002)
Inpatient hospital and post-acute care for vertebral fractures in
women. Value Health 5:301–311
30. Parker MJ, Anand JK (1991) What is the true mortality after
hip fracture. Public Health 105:443–446
31. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004)
Excess mortality after hospitalisation for vertebral fracture.
Osteoporos Int (in press)
32. Raftery J (2001) NICE: faster access to modern treatments?
analysis of guidance on health technologies. BMJ 323:1300–
1303
33. Almbrand B, Johannesson M, Sjostrand B, Malmberg K, Ry-
den L (2000) Cost effectiveness of intense insulin treatment
after acute myocardial infarction in patients with diabetes
mellitus. Eur Heart J 21:733–739
34. Kanis JA, Brazier JE, Stevenson M, Calvert WW, Lloyd Jones
M (2002) Treatment of established osteoporosis: a systematic
review and cost utility analysis. Health Technology Assessment
6(29):1–146
35. Writing Group for the Women’s Health Initiative (2002)
Risks and benefits of estrogen plus proestin in healthy post-
menopausal women: principal results from the Women’s
Health Initiative Randomized Controlled Trial. JAMA
288:321–333
36. Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect
of cholecalciferol treatment for 3 years on hip fractures in el-
derly women. BMJ 308:1081–1082
37. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson
DE, Nevitt MC et al, for the Fracture Intervention Trial Re-
search Group (1996) Randomised trial of effect of alendronate
on risk of fracture in women with existing vertebral fractures.
Lancet 348:1535–1541
38. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell
NH, for the Alendronate Phase III Treatment Study Group
(1995) Effect of oral alendronate on bone mineral density and
the incidence of fractures in postmenopausal osteoporosis.
N Engl J Med 333:1437–1443
13
39. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C,
Brandi ML et al, on behalf of the Vertebral Efficacy with
Risedronate Therapy (VERT) Study Group (2000) Rando-
mised trial of the effects of risedronate on vertebral fractures
in women with established osteoporosis. Osteoporos Int
11:83–91
40. The Osteoporosis Methodology Group and the Osteoporosis
Research Advisory Group (2002) Meta-analysis of therapies for
postmenopausal osteoporosis. Endocr Rev 23:496–507
41. Harris ST, Watts NB, Genant HK, McKeever CD, Han-
gartner T, Keller M et al, for the Vertebral Efficacy with
Risedronate Therapy (VERT) Study Group (1999) Effects of
risedronate treatment on vertebral and non-vertebral fractures
in women with postmenopausal osteoporosis. JAMA
282:1344–1352
42. Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gen-
nari C, Lopez Vaz AA, Lyritis G, Mazzuoli G, Miravet L,
Passeri M, Perez Cano R, Rapado A, Ribot C (1992) Evidence
for the efficacy of bone active drugs in the prevention of hip
fracture. BMJ 305:1124–1128
43. Keil DP, Felson DT, Anderson JJ (1987) Hip fracture and the
use of estrogens in postmenopausal women: the Framingham
Study. N Engl J Med 317:1169–1174
44. Weiss NS, Carol PH, Ure L, Ballard JH, Williams AR, Darling
JR (1980) Decreased risk of fractures of the hip and lower
forearm with postmenopausal use of oestrogen. N Engl J Med
303:1195–1198
45. Torgerson DJ, Kanis JA (1995) The cost effectiveness of pre-
venting hip fractures using vitamin D and calcium. Quart J
Med 88:135–139
46. Zethraeus N, Johannesson M, Jonsson B (1998) A computer
model to analyse the cost-effectiveness of hormone replacement
therapy. EFI Research Paper, No. 6578, January. Stockholm
School of Economics, Stockholm
47. Kanis JA, Johnell O, Oden A, Sernbo I, Redlund-Johnell I,
Dawson A, De Laet C, Jonsson B (2000) Long-term risk of
osteoporotic fracture in Malmo. Osteoporos Int 11:699–674
48. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA
(1998) Lifetime risk of hip fracture is underestimated. Osteo-
poros Int 8:599–603
49. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA, Ber-
ger M (2000) Patients with prior fractures have an increased
risk of future fractures: a summary of the literature and sta-
tistical synthesis. J Bone Miner Res 15:721–739
50. Zethraeus N, Gerdtham UG (1998) Estimating the costs of hip
fracture and potential savings. Int J Technol Assess Health
Care 14:255–267
51. Kanis JA, Dawson A, Oden A, Johnell O, De Laet C, Jonsson
B (2001) Cost effectiveness of preventing hip fractures in the
general female population. Osteoporos Int 12:356–361
52. Melton LJ, Crowson CS, O’Fallon WM (1999) Fracture inci-
dence in Olmsted County, Minnesota: comparison of urban
with rural rates and changes in urban rates over time. Osteo-
poros Int 9:29–37
53. Jones G, Nguyen PN, Sambroske PN, Kelly PJ, Gilberg C,
Eisman JA (1994) symptomatic fracture incidence in elderly
men and women. The Dubbo Osteoporosis Epidemiology
Study (DOES). Osteoporos Int 4:277–282
54. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how
well measures of bone mineral density predict occurrence of
osteoporotic fractures. Lancet 312:1254–1259
55. Johannesson M, Meltzer D, O’Connor R (1997) Incorporating
future costs in medical cost-effectiveness analysis. Med Decis
Making 7:382–389
56. Meltzer D (1997) Accounting for future costs in medical cost-
effectiveness analysis. J Health Econ 16:33–64
57. Kanis JA, Jonsson B (2002) Economic evaluation of interven-
tions for osteoporosis. Osteoporos Int 13; 765–767
58. Kanis JA, Johnell O, Black DM, Downs RW, Sarkar S, Fuerst
T, Secrest RJ, Pavo I (2003) Effect of raloxifene on the risk of
new vertebral fracture in postmenopausal women with oste-
openia or osteoporosis. Bone (in press)
59. Black DM, Thompson D, Quandt S, Palermo L, Ensrud K,
Johnell O (2002) Alendronate reduces the risk of vertebral
fracture in women with BMD T-scores above –2.5: results from
the Fracture Intervention Trial (FIT). Osteoporos Int 13[Suppl
1]:S27
60. Marens R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal
response to teriparatide is largely independent of age, initial
bone mineral density and prevalent vertebral fractures in
postmenopausal women with osteoporosis. J Bone Miner Res
18:18–23
61. Cummings SR, Black DM, Thompson DE, Applegate WB,
Barret-ConnorE,MuslinerTA, PalermoL, PrieasR,Rubin SM,
Scott JC, Vogt T,WallaceR,YatesAJ, LaCroisAZ (1998) Effect
of alendronate on risk for fractures in womenwith lowBMDbut
without vertebral fractures. JAMA 280:2077–2082
62. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG,
Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier
PJ, Reginster JY (2001) Effect of risedronate on the risk of hip
fracture in elderly women. Hip Intervention Program study
Group. N Engl J Med 344:333–340
63. Neer RM, Arnand CD, Zanchetta JR, Prince R, Gaich GA,
Reginster JY, Hodsman AB, Eriksen EF, Ishi-Shalom S,
Genant HK, Wang O, Mitlak B (2001) Effects of parathyroid
hormone (1–34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N Engl J Med 344
1434–1441
64. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D
(2000) Risk of mortality following clinical fractures. Osteopo-
ros Int 11:556–561
65. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman
JA (1999) Mortality after all major types of osteoporotic
fracture in men and women: and observational study. Lancet
353:878–882
66. Cooper C, Atkinson EJ, Jacobsen SJ, O’Fallon WM, Milton LJ
(1993) Population-based study of survival after osteoporotic
fractures. Am J Epidemiol 137:1001–1005
67. Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK,
Cummings SR, for the Study of Osteoporotic Fractures Re-
search Group (1999) Vertebral fractures and mortality in older
women. Arch Int Med 159:1215–1220
68. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby
AK (2003) The components of excess mortality after hip frac-
ture. Bone 32:468–473
69. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2003)
Excess mortality after hospitalization for vertebral fracture.
Osteoporos Int (in press)
70. Bacon WE, Maggi S, Looker A, Harris T, Nair CR, Giaconi J,
Honkanen R, Ho SC, Peffus KA, Torring O, Gass R, Gonzales
N (1996) International comparison of hip fracture rates in 1988
to 1989. Osteoporos Int 6:69–75
71. Elffors L, Allander E, Kanis JA, Gullberg B, Johnell O,
Dequeker J, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis G
et al (1994) The variable incidence of hip fracture in Southern
Europe: the MEDOS Study. Osteoporos Int 4:253–263
72. Johnell O, Gullberg B, Allander E, Kanis JA (1992) The
apparent incidence of hip fracture in Europe: a study of na-
tional register sources. Osteoporos Int 2:298–302
73. Kanis JA, Johnell O, De Laet C, Jonsson B, Oden A, Oglesby
A (2002) International variations in hip fracture probabilities:
implications for risk assessment. J Bone Miner Res 17:1237–
1244
74. Cummings SR, Eckert S, Krueger KA et al (1999) The effect of
raloxifene on risk of breast cancer in postmenopausal women:
results from the MORE randomized trial. JAMA 281:2189–
2197
75. World Health Organization (1994) Assessment of fracture risk
and its application to screening for postmenopausal osteopo-
rosis. WHO Technical Report Series, No. 843. WHO, Geneva
76. Hillner BE, Hollenberg JP, Pauker SG (1986) Postmenopausal
estrogens in prevention of osteoporosis: benefit virtually with-
out risk if cardiovascular effects are considered. Am J Med
80:1115–1127
14
